<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2025-10.4.4</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-5549</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БИОЛОГИЯ И МЕДИЦИНСКАЯ БИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOLOGY AND MEDICAL BIOLOGY</subject></subj-group></article-categories><title-group><article-title>Лизилоксидаза в патологии сердца</article-title><trans-title-group xml:lang="en"><trans-title>Lysyl oxidase in the pathology of the heart</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2540-4525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дремина</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Dremina</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дремина Наталья Николаевна – кандидат биологических наук, старший научный сотрудник лаборатории клеточных технологий и регенеративной медицины</p><p>664003, г. Иркутск, ул. Борцов революции, 1</p></bio><bio xml:lang="en"><p>Natalya N. Dremina – Cand. Sc. (Biol.), Senior Research Officer at the Laboratory of cell technologies and regenerative medicine</p><p>Bortsov Revolitsii str., 1, Irkutsk 664003</p></bio><email xlink:type="simple">drema76@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0270-404X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трухан</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Trukhan</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трухан Ирина Сергеевна – кандидат биологических наук, старший научный сотрудник лаборатории клеточных технологий и регенеративной медицины </p><p>664003, г. Иркутск, ул. Борцов революции, 1</p></bio><bio xml:lang="en"><p>Irina S. Trukhan – Cand. Sc. (Biol.), Senior Research Officer at the Laboratory of cell technologies and regenerative medicine </p><p>Bortsov Revolitsii str., 1, Irkutsk 664003</p></bio><email xlink:type="simple">predel4@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3980-050X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шурыгина</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shurygina</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шурыгина Ирина Александровна – доктор медицинских наук, профессор РАН, заместитель директора по научной работе</p><p>664003, г. Иркутск, ул. Борцов революции, 1</p></bio><bio xml:lang="en"><p>Irina A. Shurygina – Dr. Sc. (Med.), Professor of the Russian Academy of Sciences, Deputy Director for research </p><p>Bortsov Revolitsii str., 1, Irkutsk 664003</p></bio><email xlink:type="simple">irinashurygina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5921-0318</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шурыгин</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shurygin</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шурыгин Михаил Геннадьевич – доктор медицинских наук, заведующий научно-лабораторного отдела </p><p>664003, г. Иркутск, ул. Борцов революции, 1</p></bio><bio xml:lang="en"><p>Mikhail G. Shurygin – Dr. Sc. (Med.), Head of the Scientific Laboratory Department</p><p>Bortsov Revolitsii str., 1, Irkutsk 664003</p></bio><email xlink:type="simple">shurygin@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Иркутский научный центр хирургии и травматологии»</institution></aff><aff xml:lang="en"><institution>Irkutsk Scientific Center of Surgery and Traumatology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>09</month><year>2025</year></pub-date><volume>10</volume><issue>4</issue><fpage>37</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дремина Н.Н., Трухан И.С., Шурыгина И.А., Шурыгин М.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Дремина Н.Н., Трухан И.С., Шурыгина И.А., Шурыгин М.Г.</copyright-holder><copyright-holder xml:lang="en">Dremina N.N., Trukhan I.S., Shurygina I.A., Shurygin M.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/5549">https://www.actabiomedica.ru/jour/article/view/5549</self-uri><abstract><p>Сердечно-сосудистая патология на сегодняшний день является одной из главных причин инвалидизации и смертности трудоспособного населения. Одно из главных мест среди заболеваний данной патологии занимает фиброз — чрезмерное разрастание соединительной ткани. Образование фиброзной ткани определяется избыточным накоплением компонентов внеклеточного матрикса и является важной фазой репаративного процесса. Фермент лизилоксидаза и лизилоксидазоподобные белки играют важную роль в ремоделировании внеклеточного матрикса, контролируя его формирование с помощью связывания волокон коллагена или эластина. Известно, что в сердце кроме кардиомиоцитов, фибробласты представляют собой самую большую популяцию клеток, среди которых синтетически активными являются собственно фибробласты и миофибробласты, вырабатывающие волокнистые структуры внеклеточного матрикса, среди которых коллаген в сердце считается преобладающим. Из всех типов коллагена самыми распространенными являются коллагены типа I и типа III, отвечающие за прочность и эластичность матриксной сети.</p><p>Лизилоксидаза включает 5 представителей: непосредственно фермент и 4 лизиоксидазоподобных белка. Фермент и его белки — это медьсодержащие аминоксидазы, которые катализируют окисление лизина, образуя прочные поперечные связи между лизиновыми фрагментами волокнистых структур внеклеточного матрикса, регулируя его гомеостаз и ремоделирование. От состава и структуры внеклеточного матрикса напрямую зависит функциональное состояние сердца. Динамические изменения в экспрессии белков происходят при различных сердечно-сосудистых патологиях; считается, что эти изменения играют ключевую роль в связанном с ними фиброзе тканей.</p><p>Терапевтическое воздействие на ферменты семейства лизилоксидазы показало многообещающие результаты на животных моделях, но находится на ранней стадии разработки и требует дальнейшего изучения.</p><p>Проанализированы базы данных PubMed и eLibrary за период 1968–2024 гг. с использованием следующих ключевых слов: лизилоксидаза, фиброз, соединительная ткань, патология сердца.</p></abstract><trans-abstract xml:lang="en"><p>Cardiovascular pathology is currently one of the main causes of disability and mortality of the able-bodied population. Fibrosis, an overgrowth of connective tissue, occupies one of the main places among the diseases of this pathology. The formation of fibrous tissue is determined by the excessive accumulation of extracellular matrix components and is an important phase of the reparative process. The lysyl oxidase and lysyl oxidase-like proteins enzyme play an important role in the remodeling of the extracellular matrix, controlling its formation by binding collagen or elastin fibers. It is known that in the heart, in addition to cardiomyocytes, fibroblasts represent the largest population of cells, among which the synthetically active are fibroblasts and myofibroblasts, which produce fibrous structures of the extracellular matrix, among which collagen in the heart is considered predominant. Of all the types of collagen, the most common are type I and type III collagens, which are responsible for the strength and elasticity of the matrix network.</p><p>Lysyl oxidase includes 5 representatives: the enzyme itself and 4 lysyl oxidase-like proteins. The enzyme and its proteins are copper-containing amino oxidases that catalyze the oxidation of lysine, forming strong cross-links between lysine fragments of fibrous structures of the extracellular matrix, regulating its homeostasis and remodeling. The functional state of the heart directly depends on the composition and structure of the extracellular matrix. Dynamic changes in protein expression occur in various cardiovascular pathologies; It is believed that these changes play a key role in the associated tissue fibrosis.</p><p>Therapeutic effects on enzymes of the lysyl oxidase family have shown promising results in animal models, but are at an early stage of development and require further study.</p><p>The PubMed and eLibrary databases for the period 1968–2024 were analyzed using the following keywords: lysyl oxidase, fibrosis, connective tissue, heart pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лизилоксидаза</kwd><kwd>фиброз</kwd><kwd>соединительная ткань</kwd><kwd>патология сердца</kwd></kwd-group><kwd-group xml:lang="en"><kwd>lysyl oxidase</kwd><kwd>fibrosis</kwd><kwd>connective tissue</kwd><kwd>heart pathology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шурыгин М.Г., Шурыгина И.А., Дремина Н.Н., Каня О.В. Матриксная металлопротеаза 9 и ремоделирование при инфаркте миокарда. Бюллетень ВСНЦ СО РАМН. 2013; 2(90-1): 138-141.</mixed-citation><mixed-citation xml:lang="en">Shurygin МG, Shurygina IА, Dremina NN, Kanya ОV. Matrix metalloproteinase 9 and remodeling in myocardial infarction. Byulleten’ VSNC SO RAMN. 2013; 2(90-1):138-141. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021; 117(6): 1450-1488. doi: 10.1093/cvr/cvaa324</mixed-citation><mixed-citation xml:lang="en">Frangogiannis  NG. Cardiac fibrosis. Cardiovasc Res. 2021; 117(6): 1450-1488. doi: 10.1093/cvr/cvaa324</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835): 555-566. doi: 10.1038/s41586-020-2938-9</mixed-citation><mixed-citation xml:lang="en">Henderson  NC, Rieder  F, Wynn  TA. Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835): 555-566. doi: 10.1038/s41586-020-2938-9</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med. 2009; 19(8): 247-52. doi: 10.1016/j.tcm.2010.02.005</mixed-citation><mixed-citation xml:lang="en">Kania  G, Blyszczuk  P, Eriksson  U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med. 2009; 19(8): 247-52. doi: 10.1016/j.tcm.2010.02.005</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1736-1788. doi: 10.1016/S0140-6736(18)32203-7</mixed-citation><mixed-citation xml:lang="en">Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1736-1788. doi: 10.1016/S0140-6736(18)32203-7</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019; 74(20): 2529-2532. doi: 10.1016/j.jacc.2019.10.009</mixed-citation><mixed-citation xml:lang="en">Mensah  GA, Roth  GA, Fuster  V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019; 74(20): 2529-2532. doi: 10.1016/j.jacc.2019.10.009</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shurygina IА, Trukhan IS, Dremina NN, Shurygin MG. Mitogen-activated protein kinases as a target for regulating the connective tissue growth. Advances in health and disease. New York. 2023: 99-122.</mixed-citation><mixed-citation xml:lang="en">Shurygina IА, Trukhan IS, Dremina NN, Shurygin MG. Mitogen-activated protein kinases as a target for regulating the connective tissue growth. Advances in health and disease. New York. 2023: 99-122.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шурыгин М.Г., Шурыгина И.А., Дремина Н.Н., Каня О.В. Постинфарктный кардиосклероз – от патофизиологии к регенеративной медицине. Российская академия наук. Иркутск, 2017: 288.</mixed-citation><mixed-citation xml:lang="en">Shurygin MG, Shurygina  IА, Dremina  NN, Kanya  ОV. Postinfarction cardiosclerosis – from pathophysiology to regenerative medicine. Russian Academy of Sciences. Irkutsk, 2018: 288. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gillombardo CB, Hoit BD. Constrictive pericarditis in the new millennium. J Cardiol. 2024; 83(4): 219-227. doi: 10.1016/j.jjcc.2023.09.003</mixed-citation><mixed-citation xml:lang="en">Gillombardo  CB, Hoit  BD. Constrictive pericarditis in the new millennium. J Cardiol. 2024; 83(4): 219-227. doi: 10.1016/j.jjcc.2023.09.003</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Шурыгина И.А., Шурыгин М.Г., Аюшинова Н.И., Каня О.В. Фибробласты и их роль в развитии соединительной ткани. Сибирский медицинский журнал. 2012; 3: 8-12.</mixed-citation><mixed-citation xml:lang="en">Shurygina IА, Shurygin MG, Ayushinova NI, Каnya  ОV. Fibroblasts and their role in the development of connective tissue. Sibirskij medicinskij zhurnal. 2012; 3: 8-12. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tallquist MD. Cardiac Fibroblast Diversity. Annu Rev Physiol. 2020; 82: 63-78. doi: 10.1146/annurev-physiol-021119-034527</mixed-citation><mixed-citation xml:lang="en">Tallquist  MD. Cardiac Fibroblast Diversity. Annu Rev Physiol. 2020; 82: 63-78. doi: 10.1146/annurev-physiol-021119-034527</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шурыгин М.Г., Шурыгина И.А., Дремина Н.Н. Влияние фактора роста эндотелия сосудов на уровень коллагенообразования в процессе развития постинфарктного кардиосклероза. Сибирский медицинский журнал. 2008; 3: 53-55.</mixed-citation><mixed-citation xml:lang="en">Shurygin MG, Shurygina IА, Dremina  NN. The effect of vascular endothelial growth factor on the level of collagen formation during the development of postinfarction cardiosclerosis. Sibirskij medicinskij zhurnal. 2008; 3: 53-55. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018; 68-69: 490-506. doi: 10.1016/j.matbio.2018.01.013</mixed-citation><mixed-citation xml:lang="en">Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018; 68-69: 490-506. doi: 10.1016/j.matbio.2018.01.013</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rodríguez C, Martínez-González J. The Role of Lysyl Oxidase Enzymes in Cardiac Function and Remodeling. Cells. 2019; 8(12): 1483. doi: 10.3390/cells8121483</mixed-citation><mixed-citation xml:lang="en">Rodríguez C, Martínez-González J. The Role of Lysyl Oxidase Enzymes in Cardiac Function and Remodeling. Cells. 2019; 8(12): 1483. doi: 10.3390/cells8121483</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sorushanova A, Delgado LM, Wu Z, Shologu N, Kshirsagar A, Raghunath R, et al. The Collagen Suprafamily: from biosynthesis to advanced biomaterial development. Adv Mater. 2019; 31(1): e1801651. doi: 10.1002/adma.201801651</mixed-citation><mixed-citation xml:lang="en">Sorushanova  A, Delgado  LM, Wu  Z, Shologu  N, Kshirsagar  A, Raghunath  R, et  al. The Collagen Suprafamily: from biosynthesis to advanced biomaterial development. Adv Mater. 2019; 31(1): e1801651. doi: 10.1002/adma.201801651</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">López B, González A, Hermida N, Valencia F, Teresa E, Díez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010; 299(1): H1-9. doi: 10.1152/ajpheart.00335.2010</mixed-citation><mixed-citation xml:lang="en">López  B, González  A, Hermida  N, Valencia  F, Teresa  E, Díez  J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010; 299(1): H1-9. doi: 10.1152/ajpheart.00335.2010</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pinnell SR, Martin GR. The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci USA. 1968; 61: 708–716. doi: 10.1073/pnas.61.2.708</mixed-citation><mixed-citation xml:lang="en">Pinnell  SR, Martin  GR. The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci USA. 1968; 61: 708–716. doi: 10.1073/pnas.61.2.708</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Al-U’datt D, Allen BG, Nattel S. Role of the lysyl oxidase enzyme family in cardiac function and disease. Cardiovasc Res. 2019; 115(13): 1820-1837. doi: 10.1093/cvr/cvz176</mixed-citation><mixed-citation xml:lang="en">Al-U’datt D, Allen BG, Nattel S. Role of the lysyl oxidase enzyme family in cardiac function and disease. Cardiovasc Res. 2019; 115(13): 1820-1837. doi: 10.1093/cvr/cvz176</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Martínez-González J, Varona S, Cañes L, Galán M, Briones AM, Cachofeiro V, et al. Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. Biomolecules. 2019; 9(10): 610. doi: 10.3390/biom9100610</mixed-citation><mixed-citation xml:lang="en">Martínez-González J, Varona S, Cañes L, Galán M, Briones  AM, Cachofeiro  V, et  al. Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. Biomolecules. 2019; 9(10): 610. doi: 10.3390/biom9100610</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez KM, Greenaway FT. Identification of the copper-binding ligands of lysyl oxidase. Journal of Neural Transmission. 2010; 118(7): 1101–1109. doi: 10.1007/s00702-010-0559-4</mixed-citation><mixed-citation xml:lang="en">Lopez KM, Greenaway FT. Identification of the copper-binding ligands of lysyl oxidase. Journal of Neural Transmission. 2010; 118(7): 1101–1109. doi: 10.1007/s00702-010-0559-4</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Oldfield RN, Johnston KA, Limones J, Ghilarducci C, Lopez KM. Identification of Histidine 303 as the Catalytic Base of Lysyl Oxidase via Site-Directed Mutagenesis. The Protein Journal. 2018; 37: 47–57. doi: 10.1007/s10930-017-9749-3</mixed-citation><mixed-citation xml:lang="en">Oldfield  RN, Johnston  KA, Limones  J, Ghilarducci C, Lopez KM. Identification of Histidine 303 as the Catalytic Base of Lysyl Oxidase via Site-Directed Mutagenesis. The Protein Journal. 2018; 37: 47–57. doi: 10.1007/s10930-017-9749-3</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Greene AG, Eivers SB, Dervan EWJ, O’Brien CJ, Wallace DM. Lysyl Oxidase Like 1: Biological roles and regulation. Exp Eye Res. 2020: 193: 107975. doi: 10.1016/j.exer.2020.107975</mixed-citation><mixed-citation xml:lang="en">Greene  AG, Eivers  SB, Dervan  EWJ, O’Brien  CJ, Wallace  DM. Lysyl Oxidase Like 1: Biological roles and regulation. Exp Eye Res. 2020: 193: 107975. doi: 10.1016/j.exer.2020.107975</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Noda K, Kitagawa K, Miki T, Horiguchi M, O Akama T, Taniguchi T, et al. A matricellular protein fibulin-4 is essential for the activation of lysyl oxidase. Sci Adv. 2020; 6(48): eabc1404. doi: 10.1126/sciadv.abc1404</mixed-citation><mixed-citation xml:lang="en">Noda K, Kitagawa K, Miki T, Horiguchi M, O Akama T, Taniguchi T, et al. A matricellular protein fibulin-4 is essential for the activation of lysyl oxidase. Sci Adv. 2020; 6(48): eabc1404. doi: 10.1126/sciadv.abc1404</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Trackman PC. Functional importance of lysyl oxidase family propeptide regions. Journal of Cell Communication and Signaling. 2017; 12(1): 45–53. doi: 10.1007/s12079-017-0424-4</mixed-citation><mixed-citation xml:lang="en">Trackman PC. Functional importance of lysyl oxidase family propeptide regions. Journal of Cell Communication and Signaling. 2017; 12(1): 45–53. doi: 10.1007/s12079-017-0424-4</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Vallet SD, Ricard-Blum S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays Biochem. 2019; 63(3): 349-364. doi: 10.1042/EBC20180050</mixed-citation><mixed-citation xml:lang="en">Vallet SD, Ricard-Blum S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays Biochem. 2019; 63(3): 349-364. doi: 10.1042/EBC20180050</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fogelgren B, Polgár N, Szauter KM, Újfaludi Z, Laczkó R, Fong KSK, et al. Cellular Fibronectin Binds to Lysyl Oxidase with high affinity and is critical for its proteolytic activation. Journal of Biological Chemisntry. 2005; 280(26): 24690-24697. doi: 10.1074/jbc.M412979200</mixed-citation><mixed-citation xml:lang="en">Fogelgren  B, Polgár  N, Szauter  KM, Újfaludi  Z, Laczkó R, Fong KSK, et al. Cellular Fibronectin Binds to Lysyl Oxidase with high affinity and is critical for its proteolytic activation. Journal of Biological Chemisntry. 2005; 280(26): 24690-24697. doi: 10.1074/jbc.M412979200</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kalamajski S, Bihan D, Bonna A, Rubin K, Farndale RW. Fibromodulin interacts with collagen cross-linking sites and activates lysyl oxidase. J Biol Chem. 2016; 291(15): 7951-60. doi: 10.1074/jbc.M115.693408</mixed-citation><mixed-citation xml:lang="en">Kalamajski  S, Bihan  D, Bonna  A, Rubin  K, Farndale RW. Fibromodulin interacts with collagen cross-linking sites and activates lysyl oxidase. J Biol Chem. 2016; 291(15): 7951-60. doi: 10.1074/jbc.M115.693408</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rosini S, Pugh N, Bonna AM, Hulmes DJS, Farndale RW, Adams JC. Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites. Sci. Signal. 2018; 11(532): eaar2566. doi: 10.1126/scisignal.aar2566</mixed-citation><mixed-citation xml:lang="en">Rosini  S, Pugh  N, Bonna  AM, Hulmes  DJS, Farndale  RW, Adams  JC. Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites. Sci. Signal. 2018; 11(532): eaar2566. doi: 10.1126/scisignal.aar2566</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kühl U, et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011; 57(8): 977-85. doi: 10.1016/j.jacc.2010.10.024</mixed-citation><mixed-citation xml:lang="en">Kasner  M, Westermann  D, Lopez  B, Gaub  R, Escher  F, Kühl  U, et  al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011; 57(8): 977-85. doi: 10.1016/j.jacc.2010.10.024</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med. 2020; 217(3): e20190103. doi: 10.1084/jem.20190103</mixed-citation><mixed-citation xml:lang="en">Frangogiannis  N. Transforming growth factor-β in tissue fibrosis. J Exp Med. 2020; 217(3): e20190103. doi: 10.1084/jem.20190103</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022; 298(2): 101530. doi: 10.1016/j.jbc.2021.101530</mixed-citation><mixed-citation xml:lang="en">Moretti  L, Stalfort  J, Barker  TH, Abebayehu  D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022; 298(2): 101530. doi: 10.1016/j.jbc.2021.101530</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Bhattacharyya S, Midwood KS, Varga J. Tenascin-C in fibrosis in multiple organs: Translational implications. Semin Cell Dev Biol. 2022: 128: 130-136. doi: 10.1016/j.semcdb.2022.03.019</mixed-citation><mixed-citation xml:lang="en">Bhattacharyya S, Midwood KS, Varga J. Tenascin-C in fibrosis in multiple organs: Translational implications. Semin Cell Dev Biol. 2022: 128: 130-136. doi: 10.1016/j.semcdb.2022.03.019</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Laczko R, Csiszar K. Lysyl Oxidase (LOX): Functional Contributions to Signaling Pathways. Biomolecules. 2020; 10(8): 1093. doi: 10.3390/biom10081093</mixed-citation><mixed-citation xml:lang="en">Laczko  R, Csiszar  K. Lysyl Oxidase (LOX): Functional Contributions to Signaling Pathways. Biomolecules. 2020; 10(8): 1093. doi: 10.3390/biom10081093</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mohamed IA, Gadeau A-P, Hasan A, Abdulrahman N, Mraiche F. Osteopontin: a promising therapeutic target in Cardiac Fibrosis. Cells. 2019; 8(12): 1558. doi: 10.3390/cells8121558</mixed-citation><mixed-citation xml:lang="en">Mohamed  IA, Gadeau  A-P, Hasan  A, Abdulrahman  N, Mraiche  F. Osteopontin: a promising therapeutic target in Cardiac Fibrosis. Cells. 2019; 8(12): 1558. doi: 10.3390/cells8121558</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Lu M, Qin Q, Yao J, Sun L, Qin X. Induction of LOX by TGF-β1/Smad/AP-1 signaling aggravates rat myocardial fibrosis and heart failure. IUBMB Life. 2019; 71(11): 1729- 1739. doi: 10.1002/iub.2112</mixed-citation><mixed-citation xml:lang="en">Lu M, Qin Q, Yao J, Sun L, Qin X. Induction of LOX by TGF-β1/Smad/AP-1 signaling aggravates rat myocardial fibrosis and heart failure. IUBMB Life. 2019; 71(11): 1729- 1739. doi: 10.1002/iub.2112</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Galán M, Varona S, Guadall A, Orriols M, Navas M, Aguiló S, et al. Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy. FASEB J. 2017; 31(9): 3787-3799. doi: 10.1096/fj.201601157RR</mixed-citation><mixed-citation xml:lang="en">Galán M, Varona S, Guadall A, Orriols M, Navas M, Aguiló  S, et  al. Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy. FASEB J. 2017; 31(9): 3787-3799. doi: 10.1096/fj.201601157RR</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Faure E, Busso N, Nasi S. Roles of Lysyl oxidases (LOX(L)) in pathologic calcification. Biomed Pharmacother. 2024: 181: 117719. doi: 10.1016/j.biopha.2024.117719</mixed-citation><mixed-citation xml:lang="en">Faure  E, Busso  N, Nasi  S. Roles of Lysyl oxidases (LOX(L)) in pathologic calcification. Biomed Pharmacother. 2024: 181: 117719. doi: 10.1016/j.biopha.2024.117719</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Narayanan AS, Siegel RC, Martin GR. On the inhibition of lysyl oxidase by –aminopropionitrile. Biochem Biophys Res Commun. 1972; 46(2): 745-51. doi: 10.1016/s0006-291x(72)80203-1</mixed-citation><mixed-citation xml:lang="en">Narayanan  AS, Siegel  RC, Martin  GR. On the inhibition of lysyl oxidase by –aminopropionitrile. Biochem Biophys Res Commun. 1972; 46(2): 745-51. doi: 10.1016/s0006-291x(72)80203-1</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ohmura H, Yasukawa H, Minami T, Sugi Y, Oba T, Nagata T, et al. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice. Hypertens Res. 2012; 35(11): 1063-8. doi: 10.1038/hr.2012.92</mixed-citation><mixed-citation xml:lang="en">Ohmura H, Yasukawa H, Minami T, Sugi Y, Oba T, Nagata T, et al. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice. Hypertens Res. 2012; 35(11): 1063-8. doi: 10.1038/hr.2012.92</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">El Hajj EC, El Hajj MC, Ninh VK, Gardner JD. Cardioprotective effects of lysyl oxidase inhibition against volume overload-induced extracellular matrix remodeling. Exp Biol Med (Maywood). 2016; 241(5): 539-49. doi: 10.1177/1535370215616511</mixed-citation><mixed-citation xml:lang="en">El Hajj  EC, El Hajj  MC, Ninh VK, Gardner  JD. Cardioprotective effects of lysyl oxidase inhibition against volume overload-induced extracellular matrix remodeling. Exp Biol Med (Maywood). 2016; 241(5): 539-49. doi: 10.1177/1535370215616511</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Harlow CR, Wu X, van Deemter M, Gardiner F, Poland C, Green R, et al. Targeting lysyl oxidase reduces peritoneal fibrosis. PLoS One. 2017; 12(8): e0183013. doi: 10.1371/journal.pone.0183013</mixed-citation><mixed-citation xml:lang="en">Harlow  CR, Wu  X, van Deemter  M, Gardiner  F, Poland  C, Green  R, et  al. Targeting lysyl oxidase reduces peritoneal fibrosis. PLoS One. 2017; 12(8): e0183013. doi: 10.1371/journal.pone.0183013</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Franklin MK, Sawada H, Ito S, Howatt DA, Amioka N, Liang C-L, et al. β-Aminopropionitrile Induces Distinct Pathologies in the Ascending and Descending Thoracic Aortic Regions of Mice. Arterioscler Thromb Vasc Biol. 2024; 44(7): 1555-1569. doi: 10.1161/ATVBAHA.123.320402</mixed-citation><mixed-citation xml:lang="en">Franklin  MK, Sawada  H, Ito  S, Howatt  DA, Amioka N, Liang C-L, et al. β-Aminopropionitrile Induces Distinct Pathologies in the Ascending and Descending Thoracic Aortic Regions of Mice. Arterioscler Thromb Vasc Biol. 2024; 44(7): 1555-1569. doi: 10.1161/ATVBAHA.123.320402</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Chu Q, Xiao Y, Song X, Kang YJ. Extracellular matrix remodeling is associated with the survival of cardiomyocytes in the subendocardial region of the ischemic myocardium. Exp Biol Med (Maywood). 2021; 246(24): 2579- 2588. doi: 10.1177/15353702211042020</mixed-citation><mixed-citation xml:lang="en">Chu Q, Xiao Y, Song X, Kang YJ. Extracellular matrix remodeling is associated with the survival of cardiomyocytes in the subendocardial region of the ischemic myocardium. Exp Biol Med (Maywood). 2021; 246(24): 2579- 2588. doi: 10.1177/15353702211042020</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016: 7: 13710. doi: 10.1038/ncomms13710</mixed-citation><mixed-citation xml:lang="en">Yang  J, Savvatis  K, Kang  JS, Fan  P, Zhong  H, Schwartz  K, et  al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016: 7: 13710. doi: 10.1038/ncomms13710</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Y, Luo J, Song X, Gu W, Wang S, Hao S, et al. Irisin attenuates angiotensin II-induced atrial fibrillation and atrial fibrosis via LOXL2 and TGFβ1/Smad2/3 signaling pathways. Iran J Basic Med Sci. 2023; 26(6): 717-724. doi: 10.22038/IJBMS.2023.68639.14967</mixed-citation><mixed-citation xml:lang="en">Wu Y, Luo J, Song X, Gu W, Wang S, Hao S, et al. Irisin attenuates angiotensin II-induced atrial fibrillation and atrial fibrosis via LOXL2 and TGFβ1/Smad2/3 signaling pathways. Iran J Basic Med Sci. 2023; 26(6): 717-724. doi: 10.22038/IJBMS.2023.68639.14967</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Hai Z, Wu Y, Ning Z. Salidroside attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II through inhibition of LOXL2-TGF-β1-Smad2/3 pathway. Heliyon. 2023; 9(11): e21220. doi: 10.1016/j.heliyon.2023.e21220</mixed-citation><mixed-citation xml:lang="en">Hai Z, Wu Y, Ning Z. Salidroside attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II through inhibition of LOXL2-TGF-β1-Smad2/3 pathway. Heliyon. 2023; 9(11): e21220. doi: 10.1016/j.heliyon.2023.e21220</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Radhakrishnan S, Shenoy SJ, Devidasan I, Shaji BV, Gopal S, Sreekumaran S, et al. Periostin regulates lysyl oxidase through ERK1/2 MAPK-dependent serum response factor in activated cardiac fibroblasts. Cell Biochem Funct. 2024; 42(4): e4066. doi: 10.1002/cbf.4066</mixed-citation><mixed-citation xml:lang="en">Radhakrishnan S, Shenoy SJ, Devidasan I, Shaji BV, Gopal S, Sreekumaran S, et al. Periostin regulates lysyl oxidase through ERK1/2 MAPK-dependent serum response factor in activated cardiac fibroblasts. Cell Biochem Funct. 2024; 42(4): e4066. doi: 10.1002/cbf.4066</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Böhm M, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J Mol Cell Cardiol. 2015: 85: 140-50. doi: 10.1016/j.yjmcc.2015.05.019</mixed-citation><mixed-citation xml:lang="en">Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer  B, Böhm  M, et  al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J Mol Cell Cardiol. 2015: 85: 140-50. doi: 10.1016/j.yjmcc.2015.05.019</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Miguel-Carrasco JL, Beaumont J, José GS, Moreno MU, López B, González A, et al. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Sci Rep. 2017; 7: 41865. doi: 10.1038/srep41865</mixed-citation><mixed-citation xml:lang="en">Miguel-Carrasco  JL, Beaumont  J, José  GS, Moreno MU, López B, González A, et al. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Sci Rep. 2017; 7: 41865. doi: 10.1038/srep41865</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Yang N, Cao D-F, Yin X-X, Zhou H-H, Mao X-Y. Lysyl oxidases: Emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmacother. 2020: 131: 110791. doi: 10.1016/j.biopha.2020.110791</mixed-citation><mixed-citation xml:lang="en">Yang N, Cao D-F, Yin X-X, Zhou H-H, Mao X-Y. Lysyl oxidases: Emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmacother. 2020: 131: 110791. doi: 10.1016/j.biopha.2020.110791</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Ma T, Qiu F, Gong Y, Cao H, Dai G, Sun D, et al. Therapeutic silencing of lncRNA RMST alleviates cardiac fibrosis and improves heart function after myocardial infarction in mice and swine. Theranostics. 2023; 13(11): 3826-3843. doi: 10.7150/thno.82543</mixed-citation><mixed-citation xml:lang="en">Ma T, Qiu F, Gong Y, Cao H, Dai G, Sun D, et al. Therapeutic silencing of lncRNA RMST alleviates cardiac fibrosis and improves heart function after myocardial infarction in mice and swine. Theranostics. 2023; 13(11): 3826-3843. doi: 10.7150/thno.82543</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
